FDA approval allows them to begin to commercialise the software. They won't charge users directly for the use of the software. Hospitals (for example) will claim reimbursement from insurers on a per use basis. The reimbursement rates most recently advised by EIQ is $100 to $150. EIQ will take a share of that reimbursement which is their revenue. Their share will be 30-60% of the total reimbursement ($30 to $90 per use).
The MOAT is MOOT quite frankly. There are two competitors that I now know of that have developed similar software, have FDA approval, and didn't have access to the database owned by EIQ. They didn't need it so others wouldn't either.
EIQ Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)